Cargando…

Phosphate control in reducing FGF23 levels in hemodialysis patients

BACKGROUND: In hemodialysis patients, high levels of Fibroblast Growth Factor 23 (FGF23) predict mortality. Our study was designed to test whether the control of serum phosphate is associated with a reduction in serum FGF23 levels. Additionally other variables with a potential effect on FGF23 levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodelo-Haad, Cristian, Rodríguez-Ortiz, Maria E., Martin-Malo, Alejandro, Pendon-Ruiz de Mier, M. Victoria, Agüera, M. Luisa, Muñoz-Castañeda, Juan R., Soriano, Sagrario, Caravaca, Francisco, Alvarez-Lara, M. Antonia, Felsenfeld, Arnold, Aljama, Pedro, Rodriguez, Mariano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080760/
https://www.ncbi.nlm.nih.gov/pubmed/30086150
http://dx.doi.org/10.1371/journal.pone.0201537
_version_ 1783345534553030656
author Rodelo-Haad, Cristian
Rodríguez-Ortiz, Maria E.
Martin-Malo, Alejandro
Pendon-Ruiz de Mier, M. Victoria
Agüera, M. Luisa
Muñoz-Castañeda, Juan R.
Soriano, Sagrario
Caravaca, Francisco
Alvarez-Lara, M. Antonia
Felsenfeld, Arnold
Aljama, Pedro
Rodriguez, Mariano
author_facet Rodelo-Haad, Cristian
Rodríguez-Ortiz, Maria E.
Martin-Malo, Alejandro
Pendon-Ruiz de Mier, M. Victoria
Agüera, M. Luisa
Muñoz-Castañeda, Juan R.
Soriano, Sagrario
Caravaca, Francisco
Alvarez-Lara, M. Antonia
Felsenfeld, Arnold
Aljama, Pedro
Rodriguez, Mariano
author_sort Rodelo-Haad, Cristian
collection PubMed
description BACKGROUND: In hemodialysis patients, high levels of Fibroblast Growth Factor 23 (FGF23) predict mortality. Our study was designed to test whether the control of serum phosphate is associated with a reduction in serum FGF23 levels. Additionally other variables with a potential effect on FGF23 levels were evaluated. MATERIAL AND METHODS: The effect of sustained (40-weeks) control of serum phosphate on FGF23 levels (intact and c-terminal) was evaluated in 21 stable hemodialysis patients that were not receiving calcimimetics or active vitamin D. Patients received non-calcium phosphate binders to maintain serum phosphate below 4.5 mg/dl. In an additional analysis, values of intact-FGF23 (iFGF23) and c-terminal FGF23 (cFGF23) from 150 hemodialysis patients were correlated with parameters of mineral metabolism and inflammation. Linear mixed models and linear regression were performed to evaluate longitudinal trajectories of variables and the association between FGF23 and the other variables examined. RESULTS: During the 40-week treatment, 12 of 21 patients achieved the target of serum phosphate <4.5 mg/dl. In these 12 patients, iFGF23 decreased to less than half whereas cFGF23 did not reduce significantly. In patients with serum phosphate >4.5 mg, iFGF23 and cFGF23 increased two and four-fold respectively as compared with baseline. Furthermore, changes in serum phosphate correlated with changes in C-reactive protein (hs-CRP). In our 150 hemodialysis patients, those in the higher tertile of serum phosphate also showed increased hs-CRP, iPTH, iFGF23 and cFGF23. Multiple regression analysis revealed that iFGF23 levels directly correlated with both serum phosphate and calcium, whereas cFGF23 correlated with serum phosphate and hs-CRP but not with calcium. CONCLUSIONS: The control of serum phosphate reduced iFGF23. This reduction was also associated with a decreased in inflammatory parameters. Considering the entire cohort of hemodialysis patients, iFGF23 levels correlated directly with serum phosphate levels and also correlated inversely with serum calcium concentration. The levels of cFGF23 were closely related to serum phosphate and parameters of inflammation.
format Online
Article
Text
id pubmed-6080760
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-60807602018-08-16 Phosphate control in reducing FGF23 levels in hemodialysis patients Rodelo-Haad, Cristian Rodríguez-Ortiz, Maria E. Martin-Malo, Alejandro Pendon-Ruiz de Mier, M. Victoria Agüera, M. Luisa Muñoz-Castañeda, Juan R. Soriano, Sagrario Caravaca, Francisco Alvarez-Lara, M. Antonia Felsenfeld, Arnold Aljama, Pedro Rodriguez, Mariano PLoS One Research Article BACKGROUND: In hemodialysis patients, high levels of Fibroblast Growth Factor 23 (FGF23) predict mortality. Our study was designed to test whether the control of serum phosphate is associated with a reduction in serum FGF23 levels. Additionally other variables with a potential effect on FGF23 levels were evaluated. MATERIAL AND METHODS: The effect of sustained (40-weeks) control of serum phosphate on FGF23 levels (intact and c-terminal) was evaluated in 21 stable hemodialysis patients that were not receiving calcimimetics or active vitamin D. Patients received non-calcium phosphate binders to maintain serum phosphate below 4.5 mg/dl. In an additional analysis, values of intact-FGF23 (iFGF23) and c-terminal FGF23 (cFGF23) from 150 hemodialysis patients were correlated with parameters of mineral metabolism and inflammation. Linear mixed models and linear regression were performed to evaluate longitudinal trajectories of variables and the association between FGF23 and the other variables examined. RESULTS: During the 40-week treatment, 12 of 21 patients achieved the target of serum phosphate <4.5 mg/dl. In these 12 patients, iFGF23 decreased to less than half whereas cFGF23 did not reduce significantly. In patients with serum phosphate >4.5 mg, iFGF23 and cFGF23 increased two and four-fold respectively as compared with baseline. Furthermore, changes in serum phosphate correlated with changes in C-reactive protein (hs-CRP). In our 150 hemodialysis patients, those in the higher tertile of serum phosphate also showed increased hs-CRP, iPTH, iFGF23 and cFGF23. Multiple regression analysis revealed that iFGF23 levels directly correlated with both serum phosphate and calcium, whereas cFGF23 correlated with serum phosphate and hs-CRP but not with calcium. CONCLUSIONS: The control of serum phosphate reduced iFGF23. This reduction was also associated with a decreased in inflammatory parameters. Considering the entire cohort of hemodialysis patients, iFGF23 levels correlated directly with serum phosphate levels and also correlated inversely with serum calcium concentration. The levels of cFGF23 were closely related to serum phosphate and parameters of inflammation. Public Library of Science 2018-08-07 /pmc/articles/PMC6080760/ /pubmed/30086150 http://dx.doi.org/10.1371/journal.pone.0201537 Text en © 2018 Rodelo-Haad et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Rodelo-Haad, Cristian
Rodríguez-Ortiz, Maria E.
Martin-Malo, Alejandro
Pendon-Ruiz de Mier, M. Victoria
Agüera, M. Luisa
Muñoz-Castañeda, Juan R.
Soriano, Sagrario
Caravaca, Francisco
Alvarez-Lara, M. Antonia
Felsenfeld, Arnold
Aljama, Pedro
Rodriguez, Mariano
Phosphate control in reducing FGF23 levels in hemodialysis patients
title Phosphate control in reducing FGF23 levels in hemodialysis patients
title_full Phosphate control in reducing FGF23 levels in hemodialysis patients
title_fullStr Phosphate control in reducing FGF23 levels in hemodialysis patients
title_full_unstemmed Phosphate control in reducing FGF23 levels in hemodialysis patients
title_short Phosphate control in reducing FGF23 levels in hemodialysis patients
title_sort phosphate control in reducing fgf23 levels in hemodialysis patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6080760/
https://www.ncbi.nlm.nih.gov/pubmed/30086150
http://dx.doi.org/10.1371/journal.pone.0201537
work_keys_str_mv AT rodelohaadcristian phosphatecontrolinreducingfgf23levelsinhemodialysispatients
AT rodriguezortizmariae phosphatecontrolinreducingfgf23levelsinhemodialysispatients
AT martinmaloalejandro phosphatecontrolinreducingfgf23levelsinhemodialysispatients
AT pendonruizdemiermvictoria phosphatecontrolinreducingfgf23levelsinhemodialysispatients
AT agueramluisa phosphatecontrolinreducingfgf23levelsinhemodialysispatients
AT munozcastanedajuanr phosphatecontrolinreducingfgf23levelsinhemodialysispatients
AT sorianosagrario phosphatecontrolinreducingfgf23levelsinhemodialysispatients
AT caravacafrancisco phosphatecontrolinreducingfgf23levelsinhemodialysispatients
AT alvarezlaramantonia phosphatecontrolinreducingfgf23levelsinhemodialysispatients
AT felsenfeldarnold phosphatecontrolinreducingfgf23levelsinhemodialysispatients
AT aljamapedro phosphatecontrolinreducingfgf23levelsinhemodialysispatients
AT rodriguezmariano phosphatecontrolinreducingfgf23levelsinhemodialysispatients